Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 460
- Registration Number
- NCT01068678
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
Withdrawn
- Conditions
- Growth Hormone Deficiency in ChildrenGrowth Hormone Disorder
- Interventions
- Behavioral: No treatment given
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT01068639
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 403
- Registration Number
- NCT01068652
- Locations
- 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 435
- Registration Number
- NCT01059799
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Songkla, Thailand
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: biphasic insulin aspart 30Drug: insulin degludec/insulin aspart
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 424
- Registration Number
- NCT01059812
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
Effect of NN5401 in Japanese Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Drug: insulin degludec/insulin aspartDrug: biphasic insulin aspart 30
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01051102
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: insulin degludec/insulin aspartDrug: insulin glargine
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 530
- Registration Number
- NCT01045707
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: insulin glargineDrug: insulin degludec/insulin aspart
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT01045447
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kahramanmaras, Turkey
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT01046110
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
Phase 1
Terminated
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: '2-0453Drug: NNC 0070-0002-0453Drug: placebo
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 117
- Registration Number
- NCT01044108
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Evansville, Indiana, United States
© Copyright 2025. All Rights Reserved by MedPath